NDAORALTABLETPriority Review
Approved
Jul 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir) by Gilead Sciences is rna replicase inhibitors [moa]. Approved for hepatitis c virus nucleotide analog ns5b polymerase inhibitor [epc]. First approved in 2017.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VOSEVI is an oral fixed-dose combination tablet containing sofosbuvir, velpatasvir, and voxilaprevir, developed by Gilead Sciences and approved by the FDA on July 18, 2017. It is a nucleotide analog NS5B polymerase inhibitor indicated for the treatment of hepatitis C virus (HCV) infection. The triple-agent combination works through RNA replication inhibition, targeting multiple viral mechanisms to achieve high cure rates. VOSEVI represents an advancement in HCV treatment, particularly for patients with treatment-experienced or resistant HCV genotypes.
$0.0BPart D
11.6 years to LOEMechanism of Action
RNA Replicase Inhibitors
Pharmacologic Class:
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience
Started May 2016
77 enrolled
Chronic Hepatitis C
Career Relevance
VOSEVI supports a small but specialized commercial infrastructure at Gilead, including brand managers, medical science liaisons (MSLs), and field sales representatives focused on hepatology and infectious disease specialists. Roles require deep expertise in HCV epidemiology, treatment resistance mechanisms, and managed care navigation given complex payer restrictions. Currently, there are no open positions linked to this product in the available dataset.
Worked on VOSEVI at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.